{"id":53028,"date":"2023-01-18T13:02:38","date_gmt":"2023-01-18T12:02:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/veterinary-active-pharmaceutical-ingredients-manufacturing-market-report-2022-increasing-prevalence-of-zoonotic-diseases-bolsters-growth-researchandmarkets-com\/"},"modified":"2023-01-18T13:02:38","modified_gmt":"2023-01-18T12:02:38","slug":"veterinary-active-pharmaceutical-ingredients-manufacturing-market-report-2022-increasing-prevalence-of-zoonotic-diseases-bolsters-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/veterinary-active-pharmaceutical-ingredients-manufacturing-market-report-2022-increasing-prevalence-of-zoonotic-diseases-bolsters-growth-researchandmarkets-com\/","title":{"rendered":"Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2022: Increasing Prevalence Of Zoonotic Diseases Bolsters Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share & Trends Analysis Report By Service Type, By Synthesis Type, By Therapeutic Category, By Animal Type, By Region, And Segment Forecasts, 2023 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global veterinary active pharmaceutical ingredients manufacturing market size is expected to reach USD 10.64 billion by 2030. The market is expected to expand at a lucrative CAGR of 6.9% from 2023 to 2030.\n<\/p>\n

\nThe key factors driving the industry growth include the growing animal population, rising pet ownership & humanization, high pet expenditure, an increasing number of veterinarians & veterinary visits, and a high prevalence of zoonotic diseases. In addition, the rising demand for pet insurance, strategic initiatives undertaken by key participants, and government initiatives are likely to boost industry growth. Various government policies are affecting the veterinary active pharmaceutical ingredients (API) manufacturing.\n<\/p>\n

\nFor instance, in India, despite a strong base, domestic veterinary pharmaceutical companies have gradually stopped manufacturing veterinary APIs due to low-profit margins. They started importing APIs from other countries, a majority of which are imported from China, which was a cheaper alternative and increased their profit margin on drugs.\n<\/p>\n

\nThe Technology Information Forecasting and Assessment Council-an organization under the Department of Science & Technology, India-recommended a few guidelines to address the need for regulating APIs to make India self-reliant and revive its economy post-pandemic. This is important to reduce India’s dependency on China for pharmaceutical goods, including APIs, especially after the tensions between soldiers at the India-China border.\n<\/p>\n

\nVarious guidelines are being issued by government organizations to encourage veterinary services globally, which is anticipated to aid veterinary API manufacturing market growth in the coming years. An increase in the number of government initiatives that help promote animal health is also expected to fuel the overall market growth during the forecast period. The launch of One Health Initiative for enhancing animal healthcare standards has improved growth prospects for the industry.\n<\/p>\n

\nThis joint project unified clinical care, disease surveillance, and education & research areas for better control of diseases. The growing need for efficient animal treatment and increasing awareness about pathogenesis & epidemiology have encouraged organizations, such as Companion Animal Adoption Resources and the Federation of European Companion Animal Veterinary Association, to take appropriate measures.\n<\/p>\n

\nGovernment and private organizations are constantly updating their guidelines to promote animal health and prevent obesity & other disorders. This is expected to fuel industry growth over the forecast period. The increasing number of oral formulations for various veterinary drugs is boosting the demand for veterinary APIs. These majorly include nonsteroidal anti-inflammatory drugs. Manufacturers are investing in electrochemical synthesis, which helps in accelerating the manufacturing process for APIs. In addition, the introduction of biologically synthesized APIs is a technological innovation that fuels industry growth. Going forward, veterinary biopharmaceuticals produced by rDNA technology will be gaining more significance, as they would be a better choice for managing diseases, such as arthritis, cancer, & diabetes, and autoimmune disorders.\n<\/p>\n

\nFurthermore, the introduction of High-Potency APIs (HPAPIs), which act on the target cells in a much lower dose as compared to the general APIs, is also expected to offer lucrative growth opportunities in the vet API Manufacturing market. The HPAPIs are creating significant changes in pharmaceutical innovation to deliver new therapeutic medicines.\n<\/p>\n

\nVeterinary Active Pharmaceutical Ingredients Manufacturing Market Report Highlights<\/strong>\n<\/p>\n